Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant

Clinical and Laboratory Haematology

Volumn 21, Issue 4, 1999, Pages 271-275

  Cerutti, A ^a   Custodi, P ^a   Duranti, M ^a   Cazzola, M ^b   Balduini, C L ^b  

^a 'S Biagio' Hospital   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acute phase reactants; Reactive thrombocytosis; Thrombopoietin

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 6; THROMBOPOIETIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HIP SURGERY; HUMAN; MALE; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; THROMBOCYTE COUNT; THROMBOCYTOSIS;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PLATELET COUNT; STATISTICS, NONPARAMETRIC; THROMBOCYTOSIS; THROMBOPOIETIN; TIME FACTORS;

EID: 0032864755     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1999.00226.x     Document Type: Article

References (21)

1. Akahori H., Shibuia K., Obuchi M. et al. (1996) Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. British Journal of Haematology 94, 722-728.
2. Basser R.L., Rasko J.L., Clark K. et al. (1996) Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348, 1279-1281.
3. Cerutti A., Custodi P., Duranti M., Noris P. & Balduini C.L. (1997) Thrombopoietin levels in patients with primary and reactive thrombocytosis. British Journal of Haematology 99, 281-284.
4. Custodi P., Cerutti A. & Balduini C.L. (1996) Which tests are most useful to distinguish between clonal and reactive thrombocytosis? American Journal of Medicine 101, 233-235.
5. Emmons R.V.B., Reid D.M., Cohen R.L. et al. (1996) Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87, 4068-4071.
6. Fanucchi M., Glaspy J., Crawford J. et al. (1997) Effects of polyetilene-glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. New England Journal of Medicine 336, 404-409.
7. Farese A.M., Hunt P., Boone T. & MacVittie T.J. (1995) Recombinant human megakaryocyte growth and development factor stimulates thrombocytosis in normal nonhuman primates. Blood 86, 54-59.
8. Fielder P.J., Hass P., Nagel M. et al. (1997) Human platelets as a model for the binding and degradation of thrombopoietin. Blood 89, 2782-2788.
9. Folman C.C., Rensink H.J.A.M., Aarden L. et al. (1996) TPO level measurements: method of blood collection influences results. Blood 88 (Suppl. 1), 318a.
10. Harrison C.N., Gale R.E., Wienster A.C. & Skoda R.C. (1998) The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. British Journal of Haematology 102, 1341-1343.
11. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G. & Kroczek R.A. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-594.
12. Horikawa Y., Matsumura I., Hashimoto K. et al. (1997) Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 90, 4031-4038.
13. Hornkohl A., Selesi D., Bennett L., Hockmann H., Nichol J. & Hunt P. (1995) Thrombopoietin and sMPL concentrations in the serum and plasma of normal donors. Blood 86 (Suppl. 1), 898a.
14. Kuter D.J. & Rosenberg R.D. (1995) The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 85, 2720-2730.
15. Marsh J.C.W., Gibson F.M., Prue R.L. et al. (1996) Serum thrombopoietin levels in patients with aplastic anaemia. British Journal of Haematology 95, 605-610.
16. McCarty J.M. (1997) Regulation of plasma thrombopoietin (TPO) levels in reactive thrombocytosis. Blood 90 (Suppl. 1), 141a.
17. McCarty J.M., Spruegel H.K., Fox N.E., Sabath D.E. & Kaushansky K. (1995) Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 86, 3668-3675.
18. Moliterno A.L., Hankins W. & Spivak J.L. (1998) Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. New England Journal of Medicine 338, 572-580.
19. Stefanich E., Senn T., Widmer R., Fratino C., Keller G.A. & Fielder P.J. (1997) Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood 89, 4063-4070.
20. Wiestner A., Schlemper R.J., van der Maas A.P.C. & Skoda R.C. (1998) An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nature Genetics 18, 49-52.
21. Zhou W., Toombs C.F., Zou T., Guo J. & Robinson M.O. (1997) Trangenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluoruracil or antiplatelet serum treatment. Blood 89, 1551-1559.